BR0012667A - Formulações de eritropoietina de multi-doses - Google Patents

Formulações de eritropoietina de multi-doses

Info

Publication number
BR0012667A
BR0012667A BR0012667-5A BR0012667A BR0012667A BR 0012667 A BR0012667 A BR 0012667A BR 0012667 A BR0012667 A BR 0012667A BR 0012667 A BR0012667 A BR 0012667A
Authority
BR
Brazil
Prior art keywords
formulations
erythropoietin formulations
dose erythropoietin
dose
erythropoietin
Prior art date
Application number
BR0012667-5A
Other languages
English (en)
Inventor
Atef Gayed
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of BR0012667A publication Critical patent/BR0012667A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

"FORMULAçõES DE ERITROPOIETINA DE MULTIDOSES". A presente invenção é direcionada a formulações de eritropoietina de multidoses para administrações parenterais. As formulações contêm um ou mais dos conservantes seguintes cloreto de benzetónio, fenoxietanol e álcool feniletílico.
BR0012667-5A 1999-07-22 2000-07-21 Formulações de eritropoietina de multi-doses BR0012667A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19821699P 1999-07-22 1999-07-22
PCT/US2000/040446 WO2001007075A2 (en) 1999-07-22 2000-07-21 Multi-dose erythropoietin formulations

Publications (1)

Publication Number Publication Date
BR0012667A true BR0012667A (pt) 2002-07-02

Family

ID=22732468

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0012667-5A BR0012667A (pt) 1999-07-22 2000-07-21 Formulações de eritropoietina de multi-doses

Country Status (25)

Country Link
US (1) US7432360B2 (pt)
EP (1) EP1200115B9 (pt)
JP (1) JP2003517462A (pt)
KR (1) KR100693263B1 (pt)
CN (2) CN101091792A (pt)
AT (1) ATE304863T1 (pt)
AU (1) AU777397B2 (pt)
BR (1) BR0012667A (pt)
CA (1) CA2378945C (pt)
CZ (1) CZ302750B6 (pt)
DE (1) DE60022759T2 (pt)
DK (1) DK1200115T3 (pt)
EA (1) EA006220B1 (pt)
EE (1) EE200200037A (pt)
ES (1) ES2248110T3 (pt)
HK (1) HK1050318A1 (pt)
HR (1) HRP20020159B1 (pt)
HU (1) HUP0202246A3 (pt)
IL (2) IL147755A0 (pt)
NO (1) NO20020303L (pt)
NZ (1) NZ516735A (pt)
PL (1) PL202945B1 (pt)
RS (1) RS50355B (pt)
WO (1) WO2001007075A2 (pt)
ZA (1) ZA200200742B (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU4602A (sh) 1999-07-22 2005-06-10 Aventis Pharmaceuticals Inc. Farmaceutske formulacije zaštićene od dejstva mikroorganizama
BRPI0110914B8 (pt) 2000-05-15 2021-05-25 Hoffmann La Roche 'composição farmacêutica líquida, processo para preparação da mesma e uso de uma composicão farmacêutica'
MXPA06011084A (es) * 2004-03-26 2007-03-21 Johnson & Johnson Regimen de dosificacion en comunicacion para eritropoyetina.
US7772182B2 (en) 2004-08-05 2010-08-10 Alza Corporation Stable suspension formulations of erythropoietin receptor agonists
US8877234B2 (en) * 2005-02-03 2014-11-04 Clariant Finance (Bvi) Limited Preservatives
JP2011116752A (ja) * 2009-10-29 2011-06-16 Jcr Pharmaceuticals Co Ltd エリスロポエチン含有水性液剤
KR101805087B1 (ko) * 2010-09-16 2017-12-05 주식회사 엘지화학 높은 방부력을 제공하는 오일 주사 제형
BR112018008017B1 (pt) * 2015-10-22 2023-10-10 Iltoo Pharma Composição farmacêutica líquida, uso de uma composição farmacêutica líquida, método de preparação de uma composição farmacêutica líquida, kit farmacêutico e sistema de fornecimento de injeçãosubcutânea

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3489837A (en) * 1968-07-11 1970-01-13 Leroy J Hyman Synergistic antiseptic composition consisting of 9-aminoacridine hydrochloride and benzethonium chloride
JPS6045849B2 (ja) 1980-08-25 1985-10-12 林原 健 ヒトエリトロポエチンの製造方法
US4703008A (en) 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
JPS6191131A (ja) * 1984-10-09 1986-05-09 Chugai Pharmaceut Co Ltd 医薬品の吸着防止方法および組成物
JPS6197229A (ja) 1984-10-18 1986-05-15 Chugai Pharmaceut Co Ltd 安定なエリトロポエチン製剤
JPH0651637B2 (ja) * 1985-03-28 1994-07-06 エーザイ株式会社 ペプタイドの吸着防止組成物
US5045529A (en) * 1989-03-27 1991-09-03 Bionostics, Inc. Tonometric fluid for blood gas and co-oximetry instruments
JP3249147B2 (ja) * 1990-06-01 2002-01-21 キリン−アムジエン・インコーポレーテツド 生理活性蛋白含有経口製剤
CA2050425A1 (en) * 1990-09-03 1992-03-04 Yoshiaki Uda Pharmaceutical composition and its mucous use
DE4126983A1 (de) * 1991-08-15 1993-02-18 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke
US5661125A (en) 1992-08-06 1997-08-26 Amgen, Inc. Stable and preserved erythropoietin compositions
JP2532025B2 (ja) * 1993-07-23 1996-09-11 株式会社林原生物化学研究所 新リンホカインｉｉｉを有効成分とする抗腫瘍作用を有するリンホカインの活性増強剤
WO1995033474A1 (fr) * 1994-06-03 1995-12-14 Tsumura & Co. Composition medicinale
JP2000504319A (ja) * 1996-01-19 2000-04-11 イーライ・リリー・アンド・カンパニー 肥満症タンパク質製剤
BR9712824A (pt) * 1996-09-13 1999-12-21 Advanced Medicine Research Ins Composição oftálmica de fator neurotrófico, agente de tratamento de desordem funcional do nervo ótico e método para tratamento de desordem funcional do nervo ótico
JPH1112193A (ja) * 1997-06-19 1999-01-19 Sankyo Co Ltd ヒトカルシトニン含有水溶液製剤
GB9726555D0 (en) * 1997-12-16 1998-02-11 Smithkline Beecham Plc Vaccine

Also Published As

Publication number Publication date
CN1371284A (zh) 2002-09-25
HRP20020159B1 (en) 2007-08-31
NZ516735A (en) 2004-01-30
CA2378945C (en) 2010-02-23
WO2001007075A2 (en) 2001-02-01
HRP20020159A2 (en) 2003-06-30
HUP0202246A3 (en) 2010-01-28
CA2378945A1 (en) 2001-02-01
PL353569A1 (en) 2003-12-01
CN101091792A (zh) 2007-12-26
AU777397B2 (en) 2004-10-14
AU7137400A (en) 2001-02-13
ES2248110T3 (es) 2006-03-16
ATE304863T1 (de) 2005-10-15
DE60022759T2 (de) 2006-06-22
DE60022759D1 (de) 2006-02-02
IL147755A (en) 2009-11-18
JP2003517462A (ja) 2003-05-27
NO20020303D0 (no) 2002-01-21
EP1200115A2 (en) 2002-05-02
KR20020011143A (ko) 2002-02-07
EA200200073A1 (ru) 2002-08-29
EE200200037A (et) 2003-04-15
US20050267033A1 (en) 2005-12-01
EP1200115B1 (en) 2005-09-21
PL202945B1 (pl) 2009-08-31
EA006220B1 (ru) 2005-10-27
CZ2002264A3 (cs) 2002-06-12
KR100693263B1 (ko) 2007-03-13
CZ302750B6 (cs) 2011-10-19
HUP0202246A2 (en) 2002-10-28
HK1050318A1 (zh) 2003-06-20
YU4702A (sh) 2005-06-10
US7432360B2 (en) 2008-10-07
DK1200115T3 (da) 2006-01-16
ZA200200742B (en) 2003-06-25
IL147755A0 (en) 2002-08-14
EP1200115B9 (en) 2006-01-18
RS50355B (sr) 2009-11-10
NO20020303L (no) 2002-03-21
WO2001007075A3 (en) 2001-10-04

Similar Documents

Publication Publication Date Title
ATE281149T1 (de) Kosmetische zusammensetzungen
DE60033021D1 (de) Strukturierte kosmetische zusammensetzungen
DE60208355D1 (de) 2-amino-propanol derivate
PT977741E (pt) Derivados de fenilo substituido, sua preparacao e utilizacao
ID22240A (id) Komposisi shampoo penataan rambut dengan deposisi polimer penataan rambut yang ditingkatkan
DE69809755D1 (de) Substituierte 1,2,3,4-tetrahydronaphthalin derivate
DE69916329D1 (de) Kosmetische formulierung
DE69913233D1 (de) Kosmetische zusammensetzung
DE69631774D1 (de) 2,3-dioxo-1,2,3,4-tetrahydro-chinoxalin derivate
DE59804418D1 (de) Kosmetische zubereitungen
BR0012667A (pt) Formulações de eritropoietina de multi-doses
CY1106049T1 (el) Παραγωγα ινδολης
MA26848A1 (fr) Derives d'heterocyclo-alkylsufonylpyrazole nouveaux servant d'agents anti-inflammatoires/analgesiques.
ATE253360T1 (de) Acridine derivate zur verbesserung der oralen bioverfügbarkeit von taxol
DE59912915D1 (de) Herstellung von 4,4'-Diketo-carotinoiden
DE69831447D1 (de) Monopolarer elektrochirurgischer Trokar
ATE207076T1 (de) Ara-c derivate
MD502G2 (ro) Derivaţi noi ai adenozinei, procedee de preparare a lor, compoziţii farmaceutice ce le conţin
DE69834091D1 (de) Kosmetische Zubereitung
DE69710305D1 (de) Derivate von 4-Vinyl-4'-alpha-hydroxyethyl-biphenyl
DE69622415D1 (de) 12H-Dibenzo[d,g][1,3]dioxocin Derivate
FR2761064B1 (fr) Piperazines derivees d'amines cycliques, leur preparation et leur application comme medicaments
DE59803066D1 (de) Substituierte benzyloxyimino-verbindungen
NO20013715L (no) Karbamatderivater av diaryl 1,3,4-oksadiazolon
DE59707043D1 (de) Kosmetische Zubereitungen

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: AVENTIS PHARMACEUTICALS, INC. (US)

Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 020070165509/RJ DE 23/11/2007.

B25A Requested transfer of rights approved

Owner name: HMR PHARMA, INC. (US)

Free format text: TRANSFERIDO DE: AVENTIS PHARMACEUTICALS, INC.

B25A Requested transfer of rights approved

Owner name: AVENTIS HOLDINGS INC. (US)

Free format text: TRANSFERIDO DE: HMR PHARMA, INC.

B25A Requested transfer of rights approved

Owner name: AVENTISUB II INC. (US)

Free format text: TRANSFERIDO DE: AVENTIS HOLDINGS INC.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 13A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2256 DE 01/04/2014.